Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer
Cancer · 2025
DOI: 10.1002/cncr.35817 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Stephanie L Graff und 10 weiteren Autor:innen. Beteiligte Einrichtung: Brown University Health Cancer Institute, Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Background
Overall survival (OS) is the gold standard for assessing clinical benefit in oncology but requires extended follow‐up to detect sufficient events. Invasive disease‐free survival (iDFS) requires shorter follow‐up times and is considered an objective and clinically meaningful end point in early breast cancer (EBC) trials. The authors assessed iDFS as a surrogate end point for OS in adjuvant HR+/HER2– EBC using real‐world patient‐level data.
Methods
A retrospective analysis was conducted on patient data from the ConcertAI Patient360 database (January 1995–April 2021). Key inclusion criteria: age ≥18 years, stage II or III (AJCC 8th Edition) HR+/HER2– EBC, prior surgery, adjuvant endocrine therapy (ET). Spearman ρ, iterative multiple imputation ρ (IMI; 0.8–1 considered “very strong”), and R 2 (clinical relevance R 2 ≥ 0.70) were used to assess iDFS–OS relationship. Subgroup analyses included ET (nonsteroidal aromatase inhibitor or tamoxifen), stage, menopausal status, nodal status, prior (neo)adjuvant chemotherapy, and prior radiotherapy.
Results
A total of 3133 patients were included (1103 [35.2%] iDFS events; 554 [17.7%] OS events); mean age was 58.4 years, 98.8% were female, 29.9% were premenopausal, and 80.9% had stage II disease. Median follow‐up time was 55.1 months. iDFS and OS exhibited a positive, very strong, clinically relevant correlation (Spearman ρ: 0.88 [0.87–0.89]; IMI ρ: 0.83 [0.79–0.86]; both p < .0001). iDFS accounted for 82% of variation in OS (R 2 = 0.82). Results of all subgroup analyses were consistent with overall population.
Conclusions
This patient‐level real‐world analysis demonstrated very strong, positive correlations between iDFS and OS, supporting the use of iDFS as a reliable primary end point in adjuvant HR+/HER2– EBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brown University Health Cancer Institute, Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA.
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, Florida, USA.
- Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
ORCID-Profile: Stephanie L Graff, Sara M Tolaney
Förderung
- NCI NIH HHS
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Graff, S. L., Tolaney, S. M., Hart, L. L., Razavi, P., Janni, W., Schwartzberg, L. S., Danyliv, A., Akdere, M., Ferrusi, I., Adhikary, R. R., & O'Shaughnessy, J. A. (2025). Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer. Cancer. https://doi.org/10.1002/cncr.35817
Vancouver
Graff SL, Tolaney SM, Hart LL, Razavi P, Janni W, Schwartzberg LS, et al. Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer. Cancer. 2025. doi:10.1002/cncr.35817
BibTeX
@article{Graff2025,
author = {Graff, Stephanie L and Tolaney, Sara M and Hart, Lowell L and Razavi, Pedram and Janni, Wolfgang and Schwartzberg, Lee S and Danyliv, Andriy and Akdere, Murat and Ferrusi, Ilia and Adhikary, Rishi Rajat and O'Shaughnessy, Joyce A},
title = {Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35817}
}
EUVIMED